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Abstract In 2003, the uricosuric drug benzbromarone was
withdrawn from the market. The first alternative drug of
choice was the xanthine oxidase inhibitor allopurinol. The
purpose was to (1) investigate the efficacy of allopurinol
(standard dosage) compared with previous treatment with
benzbromarone; and (2) investigate the combination therapy
allopurinol–probenecid as an effective alternative treatment
compared with previous benzbromarone treatment. A pro-
spective, open study was carried out in a cohort of 51 gout
patients who discontinued benzbromarone therapy because
of market withdrawal. Patients were given 200–300 mg
allopurinol (stage 1). When allopurinol failed to attain the
target serum urate (sUr) levels ≤0.30 mmol/l, probenecid
1,000 mg/day was added (stage 2). Treatment with benz-
bromarone monotherapy (range: 100–200 mg/day; mean
138 mg/day) resulted in 92% of patients reaching target
levels sUr ≤ 0.30 mmol/l with a decrease of 61[11]%
compared to baseline. In stage 1, 32 patients completed
treatment with allopurinol monotherapy (range 200–
300 mg/day; mean 256 mg/day), which resulted in 25%
of patients attaining sUr target levels. Decrease in sUr
levels was 36[11]%, which was significantly less compared
to treatment with benzbromarone (p<0.001). In stage 2, 14
patients received allopurinol–probenecid combination ther-
apy, which resulted in 86% of patients attaining target sUr
levels (after failure on allopurinol monotherapy), which
was comparable to previous treatment with benzbromar-
one (p=0.81). Decrease in sUr levels was 53[9]% (CI
95%: 48–58%), which was a non-significant difference
compared to previous treatment with benzbromarone (p=
0.23). Benzbromarone is a very effective antihyperurice-
mic drug with 91% success in attainment of target sUr
levels ≤0.30 mmol/l. Allopurinol 200–300 mg/day was
shown to be a less potent alternative for most selected
patients to attain target sUr levels (13% success). In
patients failing on allopurinol monotherapy, the addition
of probenecid proves to be an effective treatment strategy
for attaining sUr target levels (86% success).
Keywords Allopurinol . Benzbromarone . Gout .
Probenecid . Hyperuricemia
Introduction
In 2003, benzbromarone was withdrawn from the European
market [1]. The reason for the withdrawal was the risk of
fulminant hepatitis according to the information given by
the manufacturer. Since the introduction of benzbromarone
in the early 1970s, three cases of severe hepatitis have been
published [2–4]. On the other hand, benzbromarone seems
well tolerated in general use [5] in contrast to allopurinol,
which causes frequently (2–5%) allergic skin reactions. The
uncertainty remains whether the efficacy–safety balance of
Clin Rheumatol (2007) 26:1459–1465
DOI 10.1007/s10067-006-0528-3
M. K. Reinders (*) : E. N. van Roon : J. R. B. J. Brouwers
Department of Clinical Pharmacy and Pharmacology,
Medical Centre Leeuwarden,
Henri Dunantweg 2,
8934 AD Leeuwarden, The Netherlands
e-mail: m.reinders@znb.nl
M. K. Reinders : E. N. van Roon : J. R. B. J. Brouwers
Department of Pharmacotherapy and Pharmaceutical Care,
Groningen Research Institute for Pharmacy,
University of Groningen,
Groningen, The Netherlands
P. M. Houtman : T. L. T. A. Jansen
Department of Rheumatology, Medical Centre Leeuwarden,
Leeuwarden, The Netherlands
benzbromarone really is unfavourable, compared to the
other antihyperuricemic drugs available like allopurinol,
probenecid and sulphinpyrazone [6]. In Europe, benzbro-
marone was available only as a prescription uricosuric drug
in a limited number of countries. In the Netherlands, the
only registered alternative for patients with chronic gout
was allopurinol, a uricostatic drug acting by inhibition of
xanthine oxidase.
The goal of antihyperuricemic treatment is to reduce the
serum urate (sUr) level below the threshold of supersatu-
ration to allow the dissolution of existing monosodium
urate (MSUr) crystals in the joints and to stop the
deposition of new crystals [7–11]. The solubility of urate
in joint fluids is influenced by temperature, pH, concentra-
tion of cations, level of articular dehydration and the
presence of nucleating agents such as insoluble collagens,
chondroitin sulphate and non-aggregated proteoglycans [1].
The treatment goal of antihyperuricemic therapy is usually
supposed to reach sUr levels below 0.36 mmol/l [8–10]. It
is shown that recurrent gouty attacks are better prevented
[12, 13] and that tophi dissolve more quickly [14] in the
presence of sUr levels ≤0.30 mmol/l, compared with levels
0.30–0.36 mmol/l. Thus, we aimed the sUr treatment goal
for gout patients at ≤0.30 mmol/l.
The amount of urate in the body depends on dietary
intake, synthesis and excretion. Hyperuricemia results
from the overproduction of urate (10%), from the under-
excretion of urate (90%) or often a combination of the two
[7]. Therefore, theoretically, the urate balance, in terms of
the ratio of overproduction and underexcretion of urate,
may be clinically important for the rational choice of a
uricostatic drug, a uricosuric drug or a combination of
both. However, there are no trials to support or refute this
theory [6]. From observational studies, it is concluded that
benzbromarone 75–120 mg/day is very effective in the
control of hyperuricemia, better than allopurinol 300–
450 mg/day [5, 15, 16].
We carried out an observational study to evaluate the
effectiveness of allopurinol monotherapy and combination
therapy of allopurinol with the uricosuric drug probenecid
Fig. 1 Flow of participants
through each stage of the study.
GFR Glomerular filtration rate
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in underexcretor-type and overproducer-type gout patients
previously treated with benzbromarone. Because allopuri-
nol is reported to be less potent than benzbromarone in
lowering sUr, we investigated the combination allopurinol–
probenecid as an alternative treatment when allopurinol
failed.
Materials and methods
A prospective, open label study was carried out in patients
who had to discontinue benzbromarone therapy and
contacted the rheumatology department in the period
July–December 2003. The inclusion criteria were the
following: (1) diagnosis of gout proven by presence of
MSUr crystals in the synovial fluid [17] or otherwise
complying with the American Rheumatism Association
criteria [18]; (2) pre-treatment with benzbromarone mono-
therapy of 100–200 mg/day for at least 2 months with
available sUr efficacy results; (3) no relevant liver disease
and (4) no relevant renal disease, defined as glomerular
filtration rate (GFR) >50 ml min−1 1.73 m−2.
Before entering the study, liver function, serum creati-
nine (sCr), sUr, urinary creatinine excretion (uCr) and
urinary urate excretion (uUr) on unrestricted purine diet
were measured after benzbromarone was stopped for at
least 1 month. GFR was estimated from the simplified
Modification of Diet in Renal Disease (MDRD) formula
[19, 20]. Underexcretion of urate was defined as a urate
clearance (ratio uUr/sUr) <6.0 ml min−1 1.73 m−2 [21].
Results of pre-treatment with benzbromarone were collect-
ed from the patient’s chart.
In stage 1, patients were given allopurinol with a
maximum of 200–300 mg once a day in a step-up dosage
scheme; maximum dosage prescribed depended on kidney
function, tolerability and prescriber’s preference. When the
treatment goal of sUr ≤ 0.30 mmol/l was not reached with
allopurinol after 2 months, patients were included in stage
2, and probenecid 500 mg twice daily was added to
allopurinol. Each treatment regimen was evaluated after a
treatment period of >2 months, and sCr, sUr, uCr and uUr
were measured. Prophylaxis of gouty episodes with
colchicine was prescribed to all patients until target sUr
level was reached (sUr≤0.30 mmol/l).
Table 1 Demographic data, baseline urate characteristics and previous results attained with benzbromarone of patients enrolled in stage 1
(allopurinol treatment) and enrolled in stage 2 (allopurinol–probenecid treatment)
Stage 1a Stage 2a
Allopurinol (n=50) Allopurinol–probenecid (n=14)
Demographics
Age (years) 57 [9] 55 [8]
Male gender (%) 94 93
Tophaceous gout (%) 24 14
GFR (ml min−1 1.73 m−2)
50–80 (%) 57 50
>80 (%) 43 50
History of allopurinol use (%) 20 14
Baseline urate characteristics
Baseline sUr (mmol/l), range 0.55 [0.08], 0.41–0.69 0.54 [0.08], 0.42–0.68
Baseline uUr (mmol/day), range 3.7 [1.3], 1.6–6.8 3.8 [1.7], 1.6–6.8
Baseline UrCl (ml/min), range 4.8 [1.9], 1.8–11.2 5.0 [2.5], 1.8–10.4
Underexcretor-type (%) 95 92
Previous benzbromarone resultsb
Dosage benzbromarone (mg/day) 139 [49] 143 [51]
Benzbromarone sUr (mmol/l), range 0.21 [0.07], 0.09–0.38 0.23 [0.06], 0.14–0.31
Treatment goal reached
sUr ≤ 0.30 mmol/l (%) 92 93
sUr ≤ 0.36 mmol/l (%) 98 100
Benzbromarone ΔsUr (%) −61 [11] −58 [8]
Benzbromarone uUr (mmol/day), range 5.0 [1.7], 2.4–8.5 5.3 [1.7], 2.4–8.0
Benzbromarone UrCl (ml/min), range 16.2 [4.6], 6.2–24.5 16.3 [4.9], 6.2–22.2
GFR Glomerular filtration rate, sUr serum urate, uUr urate excreted in urine, UrCl urate clearance
a Data shown as mean[standard deviation] and range, unless stated otherwise
b Latest results before benzbromarone withdrawal
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Primary endpoints for stages 1 and 2 were the percentage
of patients attaining sUr target ≤0.30 mmol/l and the
relative decrease in sUr attained with each treatment
regimen.
Statistical Package for the Social Sciences (SPSS) 14.0
for Windows was used for data collection, data validation,
data selection and statistical analysis. Student’s two-sided
paired t test and chi-squared test were used to compare the
effectiveness of benzbromarone, allopurinol and allopurinol-
probenecid therapy. Yates’s continuity correction was used
where appropriate. Normality was verified with Kolmo-
gorov–Smirnov analysis. A p value <0.05 is considered
statistically significant.
Results
Ninety patients made an appointment with the rheumatol-
ogy department because of benzbromarone withdrawal.
Fifty patients (55%) were assigned to stage 1 treatment and
received allopurinol 200–300 mg/day (Fig. 1). Table 1
shows demographic data, urate results on benzbromarone
therapy and urate results at baseline >4 weeks after
discontinuation of benzbromarone therapy. Thirty-two
patients (64%) completed stage 1 and were included in
the analysis. Eight patients attained target serum levels on
allopurinol 200–300 mg/day and completed the study.
Fourteen patients were assigned to and completed the
combination therapy allopurinol–probenecid 500 mg twice
daily (stage 2) and were included in the analysis.
Urate results after allopurinol (stage 1) and allopurinol–
probenecid (stage 2) treatment are presented in Table 2 and
Fig. 2. With allopurinol monotherapy, the sUr reached was
0.36 [0.07] mmol/l, and eight (25%) patients reached target
sUr ≤ 0.30 mmol/l. Compared to treatment with benzbro-
Fig. 2 Box-plot diagram for sUr results of stage 1, n=32 (a) and
stage 2, n=14 (b). Open circle Outlying value
Table 2 Effectiveness of allopurinol (stage 1) and allopurinol–probenecid combination therapy (stage 2)
Stage 1a Stage 2a
Allopurinol (n=32) Allopurinol–probenecid (n=14)
Dosage allopurinol (mg/day) 256 [50] 243 [51]
Dosage probenecid (mg/day) – 1,000
sUr reached (mmol/l), range 0.36 [0.07], 0.24–0.57 0.25 [0.04], 0.20–0.35
ΔsUr (%) from baseline −36 [11] −53 [9]
ΔsUr (%) from allopurinol monotherapy – −33 [10]
ΔsUr (%) from benzbromarone monotherapy +78 [60] +19 [43]
uUr (mmol/day), range 2.3 [0.8], 0.8–4.3 3.1 [0.9], 1.5–4.4
UrCl (ml/min), range 4.4 [1.3], 2.3–7.7 8.8 [2.4], 4.5–13.9
Treatment goal reached
sUr ≤ 0.30 mmol/l (%) 25 86
sUr ≤ 0.36 mmol/l (%) 53 100
sUr Serum urate, uUr urate excreted in urine, UrCl urate clearance
a Data shown as mean[standard deviation] and range, unless stated otherwise
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marone 100–200 mg/day, significantly less patients attained
target sUr levels (p<0.001). With allopurinol–probenecid,
sUr reached was 0.25 [0.04] mmol/l, and 12 (86%) patients
reached target sUr after failure on allopurinol monotherapy.
No significant difference was found compared to treatment
with benzbromarone (p=0.81).
Using allopurinol monotherapy, sUr decreased 36[11]%
compared to baseline. This was significantly less than
relative sUr decrease attained with benzbromarone in this
group (p<0.001). With allopurinol–probenecid treatment,
sUr decreased 53[9]% (CI 95%: 48–58%), which did not
significantly differ from benzbromarone (p=0.23).
Figure 3 shows cumulative probability plots of target sUr
selected and percentage of treatment success found in
stages 1 and 2 for selected target sUr and different
treatment regimens.
Discussion
First of all, this study shows that benzbromarone is a very
potent antihyperuricemic drug; in this cohort of patients using
benzbromarone 100–200 mg/day, more than 90% of the
patients have optimal sUr levels. With allopurinol standard
dosage 200–300 mg/day, comparable effectiveness cannot be
achieved for this group. The average allopurinol dosage
(mean 243 mg/day) might be considered relatively low;
however, (1) no efficacy data on allopurinol ≥600 mg/day are
available in the literature; (2) dosages >300 mg/day are
generally not advised because of increased risk of adverse
drug reactions [22]; (3) benzbromarone (mean 138 mg/day)
and probenecid (1,000 mg/day) could also be dosed
higher.
It must be noted that every patient in this study was
previously treated with benzbromarone, thereby introducing
the possibility to overestimate the percentage of responders
Fig. 3 Cumulative probability
plot of selected target sUr con-
centration and success of attain-
ment of selected target sUr for
stage 1, n=32 (a) and stage 2,
n=14 (b). Filled triangle
Benzbromarone, filled square
allopurinol, open circle allopu-
rinol–probenecid, open square
no medication, sUr serum urate
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to benzbromarone. Furthermore, a dropout occurred in
stage 1 of 38%, which may have influenced the outcome.
The relatively high dropout rate was mainly due to the
design of the study (cohort) in combination with the sudden
need for alternative treatment. On the other hand, we found
a mean relative decrease in sUr of 61% for benzbromarone
and 36% for allopurinol, which corresponds well with
values published in the literature of 54–58% for benzbro-
marone 80–125 mg/day and 27–44% for allopurinol
300 mg/day in patients not previously treated with
benzbromarone [5, 15, 16, 23, 24].
This cohort consisted of more than 90% patients of uric acid
underexcretor type. From a pathogenic point of view, it is
suggested that allopurinol, as an inhibitor of uric acid
production, would be more effective in overproducer-type
gout. However, this is not supported by clinical data [15].
Previous findings indicate that even in patients with appar-
ently high uUr, there is a relative underexcretion of urate [25].
Thus, when treatment goals are not achieved with allopurinol
in this group of patients, combination with a uricosuric drug
(e.g. benzbromarone, probenecid) might be very useful.
Adding probenecid to allopurinol contributed an addi-
tional 33[10]% (CI 95%: 28–38%) decrease in sUr on
average, resulting in reaching the target sUr for most
patients (87% success). Thus, in finding an appropriate
alternative therapy for benzbromarone, adding probenecid
to allopurinol was proven to be an effective strategy. An
interaction between allopurinol and probenecid is described
in the literature [26], resulting in an increased clearance of
oxipurinol, the active metabolite of allopurinol. However,
our data do not support this finding to be clinically
important, as the addition of probenecid to allopurinol
decreased sUr with 31% on average.
In stage 1, five patients (10%) stopped allopurinol
therapy because of adverse events related to allopurinol.
Reported events were rash, pruritus, diarrhoea, nausea and
dizziness, which are all well-known side effects of
allopurinol. Becker et al. [23] found a similar rate (12%)
of adverse events related to allopurinol.
There are few therapeutic options available to lower sUr to
target levels other than the drugs used in this study. The
uricosuric drug sulphinpyrazone is not widely used due to its
adverse effects profile [27]. Minor additive serum-lowering
effects may be achieved by losartan or fenofibrate [27, 28].
The uricostatic febuxostat may be available soon. Recently, it
was shown that when using febuxostat 80–120 mg/day, 47–
66% of the patients reached sUr levels ≤0.30 mmol/l compared
to 13% with allopurinol 300 mg/day [23]. A new promising
treatment option for patients with severe tophaceous gout is
the development of recombinant uricase [29, 30] and
pegylated recombinant uricase. Uricase-based drugs are
potentially very effective but also very expensive drugs, so
further (pharmacoeconomic) studies on optimizing antihyper-
uricemic therapy with old (out of patent) drugs, like
benzbromarone, are warranted. At this moment, benzbromar-
one seems to be the most effective antihyperuricemic drug,
and from our point of view, availability of benzbromarone in
other countries would make treatment of difficult gout more
successful [31].
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